BEDMINSTER, N.J.--(BUSINESS WIRE)--Somnus Therapeutics, Inc., a private specialty pharmaceutical company developing SKP-1041, a controlled-release, sleep-maintenance therapeutic, to treat insomnia, today announced its scientific advisory board (SAB), a panel of international sleep researchers and clinicians.
